K-ras gene and colorectal cancer therapeutic effect
10.3760/cma.j.issn.1673-422X.2014.01.017
- VernacularTitle:K-ras基因与结直肠癌疗效
- Author:
Fachang YU
;
Sheng LI
;
Zuoxing NIU
- Publication Type:Journal Article
- Keywords:
Colorectal neoplasms;
Treatment outcome;
K-ras gene
- From:
Journal of International Oncology
2014;41(3):214-216
- CountryChina
- Language:Chinese
-
Abstract:
K-ras gene is one of oncogenes,which promotes cells growth and differentiation.Ras protein loses the activity of GTP enzyme because of K-ras mutations,and that may cause abnormal growth,differentiation of cells and promote the occurrence of tumor.Patients with colorectal carcinoma that carry mutations in K-ras gene do not benefit from the administration of anti-epidermal growth factor receptor (EGFR) polyclonal antibodies.Different solid tumors of colorectal carcinoma have different K-ras mutation rates.Different genotypes of K-ras gene (wild-type or K-ras mutant type) affect significantly on treatment options and prognosis.The efficacy of mutant type patients with anti-EGFR antibodies is poor,and the therapeutic effects of 5-FU and FOLFOX are still unclear.
